The Lower Peripheral Blood Lymphocyte to Monocyte Ratio Following Completion of First Line Chemotherapy Is a Risk Factor for Predicting Relapse in Patients with Diffuse Large B-Cell Lymphoma

Background and objective: During routine follow up, there is no specific predictor to ascertain relapse after standard first line chemotherapy in diffuse large cell lymphoma. Therefore, this study was designed to assess the prognostic significance of the ratio between absolute lymphocyte and monocyte counts (LMR) in the peripheral blood to verify relapse in diffuse large B cell lymphoma. Patients and methods: A total of 139 patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) were evaluated and treated with CHOP or R-CHOP between the years 2009 and 2016. Three months following completion of first line therapy, Lymphocyte/monocyte ratio (LMR) was calculated from the routine automated complete blood cell count (CBC) attained a plateau after the bone marrow recovery after first line chemotherapy. The absolute lymphocyte count/absolute monocyte count ratio (LMR) was calculated by dividing the ALC by the AMC. Results: ROC curve analysis of 139 patients established 2.8 as cutoff point of LMR for relapse with AUC of 0.97 (95% CI 0.93 0.99, P ≤ 0.001). Cox regression analysis was performed to identify factors predicting relapse. In univariate regression analysis, ALC (95% CI 0.003 0.03, p ≤ 0.001), AMC (95% CI 15.4 128.8, p ≤ 0.001), LMR (95% CI 0.001 0.01, p ≤ 0.001), and LDH (95% CI 0.1 0.5, p ≤ 0.001) following completion of therapy are significant factors for relapse. Other significant factors for relapse are Ann Arbor stage (95% CI 1.1 6.9, P = 0.03), extranodal sites (95% CI 1.2 6.1, P = 0.01), age (95% CI 1.3 6.5, P = 0.01) and treatment of CHOP protocol (95% CI 0.05 0.6, P = 0.007). In a multivariate analysis LMR following completion of therapy was predictive for relapse How to cite this paper: Eladawei, G.E. and El-Taher, S.M. (2019) The Lower Peripheral Blood Lymphocyte to Monocyte Ratio Following Completion of First Line Chemotherapy Is a Risk Factor for Predicting Relapse in Patients with Diffuse Large B-Cell Lymphoma. Journal of Cancer Therapy, 10, 53-68. https://doi.org/10.4236/jct.2019.101005 Received: December 18, 2018 Accepted: January 20, 2019 Published: January 23, 2019 Copyright © 2019 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0). http://creativecommons.org/licenses/by/4.0/


Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of lymphoid neoplasm as it represents 25% -30% of all newly diagnosed cases of adult Non-Hodgkin lymphoma (NHL) [1].Although it is an aggressive type of lymphoma, it is potentially curable.
The routine addition of rituximab therapy improved the overall survival of patients with DLBCL.However, approximately one-third of the patients develop relapsed/refractory disease that remains a major cause of morbidity and mortality [2].
Clinical outcome in DLBCL patients treated with standard therapy is assessed by risk factors before treatment implementation, such as the international prognostic index (IPI) [3], Immunohistochemistery-based detection [4] [5] or gene expression profiling [6] [7].
Immunodeficiency is one of the strongest risk factors of non-Hodgkin lymphoma [8].Gene-expression profiling (GEP) studies showed a relationship between lymphoma biology and the host immune system, and suggested that gene signatures related to nonmalignant tumor microenvironment played an important role in the clinical outcomes of patients with NHL [9] [10] [11].
In spite of the fact that specific gene signatures of host immunity can predict prognosis of DLBCL patients, it is impractical for application on routine basis due to coast and technical limitation.Therefore, a large number of studies have therefore focused on the search for surrogate biomarkers which are immunologically relevant and can serve as prognostic factors [11] [12] [13].
During follow up after standard therapy in DLBCL, lactic dehydrogenase (LDH) is an inexpensive factor that helps to identify patients who might require further evaluation for relapse.LDH has been reported to have a sensitivity of 42% and a specificity of 85% to predict relapse during follow-up [14].

Patients & Methods
This is retrospective study was conducted in clinical oncology & nuclear medicine, Mansoura University between the years 2009 and 2016.A total 139 patients with newly diagnosed diffuse large B cell lymphoma (DLBCL) who were evaluated and treated with CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone) or R-CHOP (rituximab-cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone).
We excluded patients with primary DLBCL central nervous system lymphoma, transformed NHL, positive human immunodeficiency virus, who underwent upfront autologous stem cell transplantation during first line treatment or progressed during standard first line chemotherapy or lost follow up.

Study Objective
The primary aim of the study was to assess the ability of the LMR after completion of first-line therapy to predict relapse of DLBCL.We also evaluated whether the LMR affected overall survival (OS) and disease-free survival (DFS); we performed a landmark analysis commencing 3 months after completion of chemotherapy when the patients were in complete remission which was confirmed by CT scans.
Following completion of first line therapy, we calculated LMR from the routine automated complete blood cell count (CBC) attained a plateau after the bone marrow recovery after first line chemotherapy.In our routine follow up CBC was done after 3 months after completion of chemotherapy.Therefore, we used the LMR data from the 3-month follow-up visits.
The absolute lymphocyte count/absolute monocyte count ratio (LMR) was calculated by dividing the ALC by the AMC.
Response and relapse criteria were based on the criteria from the International Harmonization Project [18].Overall survival (OS) was measured from the day following completion of first-line therapy until the date of death from any cause, or date of the last follow-up.Disease free survival (DFS) measured from the day following completion of first-line therapy until the date of first lymphoma relapse, death from any cause, or date of the last follow-up.Follow-up procedures usually included a physical examination, blood tests

Statistical Analysis
All statistical analyses were performed using SPSS statistical software (version 21).Receiver operating characteristic (ROC) curve analysis was used to determine the optimal LMR cutoffs yielding the maximal combined sensitivities and specificities.
Correlations of the ALC, AMC, and LMR with clinical parameters were evaluated using the chi-square or Fisher's exact test.OS and PFS were analyzed using Kaplan-Meier curves, which were compared using the log-rank test.Cox regression model was applied in both univariate and multivariate analyses to prognostic variables to predict relapse.Categorical variables were compared using the chi-square test.P value of <0.05 was considered statistically significant.

Patient Characteristics
Retrospectively, we analyzed data of a total 139 DLBCL patients in this study.

Cut off Values for the ALC, AMC, and LMR as Marker for Relapse
The choice of the best cutoff in predicting relapse was selected by receiver operating characteristic (ROC) curves and calculated areas under the curves (AUCs).(94.9% p = 0.001).However ECOG performance did not differ significantly between the two groups (Table 3).

Discussion
In spite of addition of anti-CD 20 monoclonal antibody rituximab in treatment of diffuse large B cell lymphoma, significant percentage of patients relapsed and that remain a major cause of mortality and morbidity [19].
The main objective of follow-up is to detect early relapse in order to improve Comprehensive Cancer Network [20].Moreover, follow-up every 3 months for 1 year, every a half year for two years and afterward once per year in NHL patients was recommended by the European Society of Medical Oncology [21].
Careful history, physical examination and good clinical judgment are the most important items in monitoring patients after treatment [18].More than 80% of relapse can be determined by patients or physicians, so regular surveillance CT scans is unsatisfactory for prediction of relapse [22] [23].Furthermore, false positive results are frequent and unnecessary biopsies or additional scans will be done without need [24].
In asymptomatic DLBCL patients who achieved a complete response, routine assessment of lactic dehydrogenase is not recommended [25].So, currently both ESMO and NCCN recommended follow up by blood counts and repeating CT scans only when clinically indicated [26].
Recently, gene expression profiling studies in NHL stated that gene expression by tumor-infiltrating lymphocytes and myeloid derived cells predict clinical outcome [17] [18].
In NHL patients, Lymphocytes have an important role in immune surveillance.Lymphopenia is considered a surrogate marker of host immunological incompetence [27] [28] [29] Furthermore, lymphocytes may be required for rituximab-mediated, antibody-dependent cell mediated cytotoxicity-dependent destruction of malignant B cells.Accordingly, lymphopenia is an adverse prognostic factor in indolent and aggressive NHL, including DLBCL [30].
Tumorigenesis and angiogenesis were promoted by myeloid-lineage cells, including monocytes and their progeny [29], These cells lead to the suppression of antitumor immunity and then, development of neutrophilia or monocytosis in the peripheral blood which are considered adverse prognostic factors in multiple solid tumors [30] [31] [32].
The LMR biomarker reflects the status of both immune homeostasis and the tumor microenvironment after treatment.LMR was shown to be an independent prognostic marker in patients with DLBCL patients [33].
In was significantly correlated with early relapse in both univariate and multivariate analysis [26].Our result was in accordance with those previous studies.On the other hand, YAMAUCHI et al. 2015 reported that low lymphocytes monocytes ratio was not predictive for disease relapse of advanced DLBCL [35].
In the present study, we observed that patients with high LMR ≥ 2.8 after first line chemotherapy achieved significantly better PFS and longer survival than those with LMR.Many studies observed that low LMR is prognostic marker for survival of diffuse large B cell lymphoma patients [15] [16] [36] [37] [38].Furthermore, an updated meta-analysis including twelve studies was performed to assess the relation between low LMR and survival of patients with diffuse large B-cell lymphoma.The meta-analysis stated that low LMR has adverse effect and poor survival of patients with diffuse large B cell lymphoma [33].

Conclusion
The current study is retrospective with relatively low number of patients to allow

Figure 1 .
Figure 1.(a) Receiver operating characteristic (ROC) curve of absolute lymphocyte count as a marker for relapse.(b) Receiver operating characteristic (ROC) curve of absolute monocyte count as a marker for relapse.(c) Receiver operating characteristic (ROC) curve of lymphocyte monocyte ratio (LMR) as a marker for relapse.

G
. E. Eladawei, S. M. El-Taher DOI: 10.4236/jct.2019.10100563 Journal of Cancer Therapy outcome.Long term follow up according to the clinical indications or every 3 -6 months in patients with DLBCL was currently recommended by the National confirmation of diagnosis.So to minimize these biases we selected only patients with de novo DLBCL treated with standard first line chemotherapy.In addition, receiver operating characteristic curves and area under the curve were used to determine the best ALC, AMC, LMR cutoff value.This study observed that LMR assessed after first line chemotherapy during routine follow up is an independent predictor of relapse and clinical outcome in DLBCL patients.LMR at follow up can be used a simple inexpensive biomarker to alert clinicians of relapse during follow up after standard first line chemotherapy in DLBCL patients.
The most discriminative cutoff value of ALC was 1170 cells/UL with AUC of G. E. Eladawei, S. M. El-Taher DOI: 10.4236/jct.2019.10100557 Journal of Cancer Therapy ECOG Eastern Cooperative Oncology Group, PS performance status, IPI International Prognostic Index, LDH lactate dehydrogenase.

Table 3 .
Prognostic factors for predicting relapse.

Table 4 .
Logistic regression univariate and multivariate analysis for relapse.
[34]current study, the choice of best cutoff values of ALC, AMC and LMR Li et al. 2014 retrospectively analyzed blood lymphocyte/monocyte ratio during routine follow up after standard first line chemotherapy (CHOP or R-CHOP).Patients with an ALC/AMC ratio (<2.8) had a higher cumulative hazard rate of relapse compared with those had ALC/AMC ratio ≥ 2.8 (p ≤ 0.001)[34].Also, Zhou et al. 2017 stated that Low lymphocyte/monocyte ratio < 2.9 risk of relapse could be the result of either, failure of immune surveillance leading to clinical relapse or primary relapse produce mediators of immune suppression expressed as a decrease in ALC and a elevate in AMC.G. E. Eladawei, S. M. El-Taher DOI: 10.4236/jct.2019.10100564 Journal of Cancer Therapy